← Leaderboards
Rosa Bacchetta
Stanford University
$2,223,336
Attributed
$2,442,682
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $669.6K · FY2017–24$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
FDA$2,003,989 · 1
NIH$438,693 · 1
By mechanism
R01$2,003,989 · 1
R21$438,693 · 1
Top collaborators
- Matthew H Porteus2 shared
Most similar at Stanford University
Same institution · by research overlap
- Kari C. Nadeau$30,132,783
- Gideon Lack$3,214,542
- Stephen J Galli$26,066,229
- Sean E O'Leary$2,937,937
- Seung K Kim$34,748,747
Others in their field
Other Emerging Leaders on “Affect”
- Chanza Baytop · Westat, Inc.$271,217,917
- Leonard Freedman · Leidos Biomedical Research, Inc.$62,378,387
- Jennifer Marie Suga · Kaiser Foundation Research Institute$29,218,159
- Lynn Briscoe · Leidos Biomedical Research, Inc.$27,788,199
- George Robert Painter · University Of Alabama At Birmingham$27,619,145
- Jessica Brooke Langbaum · Banner Health$22,633,312
Research focus
AffectAllogenicAutoantibodiesAutoimmune DiseasesAutoimmune ProcessAutoimmunityAutologousBaseCd34 GeneCdna ExpressionCell PhysiologyCellsCell TherapyCell TypeChildChronicClone CellsClustered Regularly Interspaced Short Palindromic RepeatsComplementary DnaConditioningCrispr/Cas TechnologyCytokineDefectAcute
Grant awards (5)
Phase 1 Study of Autologous CD4LVFOXP3 in Participants with IPEX Syndrome [revised IND and clinical protocol to be submitted to FDA by 10/11/2021]$669,615
R01 · FY2024 · FD · contact PI
Phase 1 Study of Autologous CD4LVFOXP3 in Participants with IPEX Syndrome [revised IND and clinical protocol to be submitted to FDA by 10/11/2021]$665,892
R01 · FY2023 · FD · contact PI
Phase 1 Study of Autologous CD4LVFOXP3 in Participants with IPEX Syndrome [revised IND and clinical protocol to be submitted to FDA by 10/11/2021]$668,482
R01 · FY2022 · FD · contact PI
Genome Editing to rescue FOXP3 Deficiency in IPEX syndrome$239,135
R21 · FY2018 · AI · contact PI
Genome Editing to rescue FOXP3 Deficiency in IPEX syndrome$199,558
R21 · FY2017 · AI · contact PI